RoundTable Healthcare Partners has announced its investment in Colorescience, a US-based skincare and sun protection brand with a strong foothold in dermatology and medical aesthetics. The deal, announced February 2, comes at a time when sunscreen brands are being forced to rethink how they fit into consumers’ everyday routines.
A daily-use message in a value-driven market
Colorescience’s portfolio centers on mineral sun protection positioned as part of everyday skincare rather than occasional outdoor use. That approach mirrors broader shifts in the category, where consumers are becoming more selective as personal care spending rises.
Market research firm Mintel has found that “as personal care routines become increasingly expensive, consumers are streamlining their suncare habits,” with growth slowing even in segments that had previously expanded quickly. According to the firm, “even previously growing sectors, such as hybrid suncare, are experiencing their first decline in years.”
At the same time, Mintel has pointed to “rising popularity of mineral-based and clean-label claims,” as well as greater demand for textures that feel comfortable enough for repeated, year-round use.
These preferences have increased pressure on brands to balance efficacy with wearability rather than rely on novelty. As previously reported by CosmeticsDesign-US (CDU), some novel sunscreen formats have received increased FDA scrutiny and therefore increase risk for brands experimenting in this space.
In the company’s press announcement, Mary Fisher, CEO of Colorescience, said the brand’s progress has been driven by consistency and focus. “Since 2013, our team has built Colorescience into a trusted brand that delivers meaningful protection and performance for our customers,” she said.
Regulatory change adds another layer
Looking ahead, regulatory developments could further reshape the US sunscreen landscape. Mintel has noted that “the anticipated FDA approval of BEMT – the first new UV filter in two decades – could signal a significant reset for the sunscreen category,” particularly as US consumers become more familiar with international products known for lighter textures and strong dermatological backing.
As previously reported by CDU, FDA announced a proposed order adding bemotrizinol (BEMT) to the list of permitted sunscreen ingredients in December 2025.
Against that backdrop, RoundTable described Colorescience as a platform with room to grow without losing its clinical identity.
“Colorescience has built a compelling platform defined by strong consumer advocacy and a differentiated product portfolio anchored by a commitment to science and innovation,” Tim Connors, Managing Partner of RoundTable and chairman of Colorescience’s board, said in the company’s press release.
Financial terms of the investment were not disclosed. Looking ahead, Adele Oliva, Founding Partner of 1315 Capital, whose firm has partnered with RoundTable on multiple transactions, stated, “the growth of Colorescience over the past few years has been tremendous, and we are excited about RoundTable’s impact on the trajectory ahead.”
